Investment Highlights

With new and unique technologies and active substances, the biopharmaceutical company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

What sets us apart:

  • Biopharmaceutical company developing ground-breaking immunotherapies
  • Lead product lefitolimod (MGN1703): potential blockbuster candidate
  • Targeting indications with high unmet medical needs: Cancer and HIV
  • Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules

Annual Report 2016
Download PDF

Quarterly Statement as at 31 March 2017
Download PDF

Half-year Report as at 30 June 2017
Download PDF

Quarterly Statement as at 30 September 2017

Download PDF

May 4, 2018

Annual General Meeting

March 22, 2018
Annual Report 2017

 

Show complete Corporate Calendar.

March 4 - March 7, 2018

CROI Conference on Retroviruses and Opportunistic Infestions (HIV), Boston, USA

 

February 26 - February 27, 2018

Sach European Life Science CEO Forum & Exhibition, Zurich, Switzerland

 

February 5 - February 6, 2018

4th Biotech and Money / Medtech and Money World Congress 2018, London, UK


Show complete calendar.

 

 

 

 

Capital increase 2018 from authorized capital

Further Information

Share Price

Contact:

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.